Children with spastic cerebral palsy (CP) often walk with insufficient ankle dorsiflexion in the swing phase. A pathological gait, known as drop-foot gait, can be the result and this has 2 major complications: foot-slap during loading response and toe-drag during swing. This is partly caused by weakness of the anterior tibial muscle and partly due to co-contraction of both the fibular- and anterior tibial muscle. For classification of gait, the Winters scale can be used, where unilateral CP with dropfoot is classified as type I. In daily life these problems cause limited walking distance and frequent falls, leading to restrictions in participating in daily life. The current guideline for spastic cerebral palsy describes the following therapies: 1) conservative therapy (physiotherapy, orthopaedic shoes and orthoses) 2) drugs suppressing spasticity 3) surgical interventions. Functional electrical stimulation (FES) may be an effective alternative treatment for children with spastic CP and a drop foot. By stimulating the fibular nerve or the anterior tibial muscle directly during the swing phase, dorsiflexion of the foot is stimulated. In contrast to bracing, FES does not restrict motion, but does produce muscle contraction, and thus has the potential to increase strength and motor control through repetitive neural stimulation over time. In a systematic review the investigators found that FES immediately improves ankle dorsal flexion and reduces falls and these effects also sustain. However, it should be noted that the level of evidence is limited. Until now, the use of FES in CP is limited and no data exist about the effects on walking distance (activity level) and participation level. The overall objective of this study is to conduct a randomised cross-over intervention trial in children with unilateral spastic CP with 12 weeks of FES (for every participant) and 18 weeks of conventional therapy. The effectiveness of FES will be examined at participation leven, using individual goal attainment. Next to that the effect at gait will be measured. An additional goal is to investigate the cost effectiveness of FES, which, in case of a positive effect, may support allowance by insurance companies.
Children with spastic cerebral palsy often walk with insufficient ankle dorsiflexion in the swing phase or with eversion of the foot. A pathological gait, known as drop-foot gait, can be the result and this has 2 major complications: foot-slap during loading response and toe-drag during swing. This is partly caused by weakness of the anterior tibial muscle and partly due to co-contraction of both the fibular- and anterior tibial muscle. In time, the disorder appears to be progressive due to atrophy and contractures of the muscle and increasing bodyweight. For classification of gait, the Winters scale can be used, where unilateral CP with dropfoot is classified as type I. In daily life these problems cause limited walking distance and frequent falls. This can lead to restrictions in participating in daily activities at school and in leisure. The current guideline for spastic cerebral palsy describes the following therapies: 1) conservative therapy, which includes physiotherapy, orthopaedic shoes and orthoses. 2) systemically and locally applied drugs suppressing spasticity. 3) surgical interventions, e.g. tenotomy, transposition and osteotomy. In each intervention, there is the risk of side effects, such as sedation with oral medications, pressure sores and atrophy in a static orthosis, temporary effect in a Botulinum toxin A treatment and surgical complications due to a result of the surgery, and on the other hand as a result of the execution. Functional electrical stimulation (FES) may be an effective alternative treatment for children with spastic CP and a drop foot. By stimulating the fibular nerve or the anterior tibial muscle directly during the swing phase, dorsiflexion of the foot is stimulated. In contrast to bracing, FES does not restrict motion, but does produce muscle contraction, and thus has the potential to increase strength and motor control through repetitive neural stimulation over time. In a systematic review the investigators found that FES immediately improves ankle dorsal flexion and falls. In addition, longer sustained effects of FES on ankle dorsal flexion and falls are found. However, it should be noted only two study studies (4 articles) were of level II class evidence (small RCT) and all other studies used a single subject design. Until now, the use of FES in CP is limited and no data exist about the effects on walking distance (activity level) and participation level. The overall objective of this study is to conduct a randomised cross-over intervention trial in children with unilateral spastic CP with 12 weeks of FES for every participant and 18 weeks of conventional therapy. The effectiveness of FES will be examined at participation leven, using individual goal attainment. With every individual a goal at walking distance will be set, next to possible other goals. Next to that, results will be measured at the activity and functional level: the effect at gait kinematics (such as ankle dorsiflexion and balance), walking distance, falls, spasticity and muscle force. The type of brain damage of the patients is also taken in to account. An addition al goal is to investigate the cost effectiveness of FES, which, in case of a positive effect, may support allowance by insurance companies.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
25
Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.
Maastricht University Medical Center
Maastricht, Limburg, Netherlands
Change in goal attainment scale (GAS)
Goal attainment scale: definition of an individual goal at start, followed by a 6- point numeric scale indicating to what extent the goal is (score 0 till +2) or is not (-3 indicating detoriation till -1) reached.
Time frame: Setting of goal(s) at start, assessment at every end of a phase: week 12, 18 and 30.
Change in participation
as measured in the Cerebral Palsy Quality of Life Questionnaire (see reference).
Time frame: assessment at start and every end of a phase: week 12, 18 and 30.
Change in walking distance
Measured by the 6 minute walking test and the functional mobility scale (3 items, 6-point rating scale).
Time frame: assessment at start and every end of a phase: week 12, 18 and 30.
Change in physical activity
measured by activity monitor
Time frame: assessment at start and end of a phase (except for the wash-out phase): week 12 and 30.
Change in frequency of falling
measured by a questionnaire
Time frame: assessment at every end of a phase: week 12, 18 and 30.
Change in stability during walking
measured by variation of center of mass and margins of stability assessed during 3D gait analysis
Time frame: assessment at start and every end of a phase: week 12, 18 and 30.
Change in ankle dorsiflexion angle
measured in degrees during gait analysis during 3D gait analysis
Time frame: assessment at start and every end of a phase: week 12, 18 and 30.
Change in calf muscle activation
Assessed by spasticity measurement and electromyography (EMG) during 3D gait analysis
Time frame: assessment at start and every end of a phase: week 12, 18 and 30.
Change in ankle plantarflexion strength during walking
Calculated by net push off moments during 3D gait analysis
Time frame: assessment at start and every end of a phase: week 12, 18 and 30.
Change in ankle dorsiflexion and plantarflexion strength
measured in Newton by handheld dynamometer
Time frame: assessment at start and every end of a phase: week 12, 18 and 30.
Change in feelings about donning and doffing
measured by a questionnaire
Time frame: assessment at start and every end of a phase: week 12, 18 and 30.
Change in patient satisfaction
measured by a visual analogue scale with smileys (0 = unsatisfied, 6 = perfectly satisfied).
Time frame: assessment at start and every end of a phase: week 12, 18 and 30.
The compliance and acceptability of FES
derived from delivered stimulations and hours of wear time in the log file
Time frame: the FES devices measures this automatically during wearing; so this will happen during the 12 weeks of FES therapy
Type of brain lesion in relation to FES success
Derived from available brain imaging
Time frame: Assessment and analysis of available imaging will be done after completion of the study by the patient, so after week 30, up to week 50 to collect a batch of finished patients. No imaging will be performed because of the study.
Cost-effectiveness of FES
compared to conventional therapy
Time frame: analysis after study completion, week 30, using the EQ-5D-Y results.
Change in health
EQ-5D-Y Questionnaire, youth version
Time frame: assessment at every end of a phase: week 12, 18 and 30.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.